These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34544507)

  • 41. Generalized neurocognitive impairment in individuals at ultra-high risk for psychosis: The possible key role of slowed processing speed.
    Randers L; Jepsen JRM; Fagerlund B; Nordholm D; Krakauer K; Hjorthøj C; Glenthøj B; Nordentoft M
    Brain Behav; 2021 Mar; 11(3):e01962. PubMed ID: 33486897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation of social and cognitive predictors in non-transition ultra-high-risk' individuals for psychosis using spiking neural networks.
    Doborjeh Z; Doborjeh M; Sumich A; Singh B; Merkin A; Budhraja S; Goh W; Lai EM; Williams M; Tan S; Lee J; Kasabov N
    Schizophrenia (Heidelb); 2023 Feb; 9(1):10. PubMed ID: 36792634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship of obsessive-compulsive symptoms to clinical variables and cognitive functions in individuals at ultra high risk for psychosis.
    Soyata AZ; Akışık S; İnhanlı D; Noyan H; Üçok A
    Psychiatry Res; 2018 Mar; 261():332-337. PubMed ID: 29334657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship of negative symptom severity with cognitive symptoms and functioning in subjects at ultra-high risk for psychosis.
    Üçok A; Direk N; Kaya H; Çağlar N; Çıkrıkçılı U; Noyan H; Yokuşoğlu Ç; Devrim-Üçok M
    Early Interv Psychiatry; 2021 Aug; 15(4):966-974. PubMed ID: 32945138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Episodic memory dysfunction in individuals at high-risk of psychosis: a systematic review of neuropsychological and neurofunctional studies.
    Valli I; Tognin S; Fusar-Poli P; Mechelli A
    Curr Pharm Des; 2012; 18(4):443-58. PubMed ID: 22239575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive course in first-episode psychosis and clinical correlates: A 4 year longitudinal study using the MATRICS Consensus Cognitive Battery.
    Kenney J; Anderson-Schmidt H; Scanlon C; Arndt S; Scherz E; McInerney S; McFarland J; Byrne F; Ahmed M; Donohoe G; Hallahan B; McDonald C; Cannon DM
    Schizophr Res; 2015 Dec; 169(1-3):101-108. PubMed ID: 26416442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive functioning in young people with first episode psychosis: relationship to diagnosis and clinical characteristics.
    Fitzgerald D; Lucas S; Redoblado MA; Winter V; Brennan J; Anderson J; Harris A
    Aust N Z J Psychiatry; 2004 Jul; 38(7):501-10. PubMed ID: 15255822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings.
    Meijer JH; Dekker N; Koeter MW; Quee PJ; van Beveren NJ; Meijer CJ;
    Psychol Med; 2012 Apr; 42(4):705-16. PubMed ID: 21899795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and neurocognitive profiles of subjects at high risk for psychosis with and without obsessive-compulsive symptoms.
    Hur JW; Shin NY; Jang JH; Shim G; Park HY; Hwang JY; Kim SN; Yoo JH; Hong KS; Kwon JS
    Aust N Z J Psychiatry; 2012 Feb; 46(2):161-9. PubMed ID: 22311532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition.
    Wenneberg C; Nordentoft M; Rostrup E; Glenthøj LB; Bojesen KB; Fagerlund B; Hjorthøj C; Krakauer K; Kristensen TD; Schwartz C; Edden RAE; Broberg BV; Glenthøj BY
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Jun; 5(6):569-579. PubMed ID: 32008981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The relationship between level of cognitive impairments and functional outcome trajectories in first-episode schizophrenia.
    Fu S; Czajkowski N; Rund BR; Torgalsbøen AK
    Schizophr Res; 2017 Dec; 190():144-149. PubMed ID: 28302394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The relevance of processing speed in the functioning of people with first-episode psychosis.
    Abella M; Vila-Badia R; Serra-Arumí C; Vallejo-Rius G; Colomer-Salvans A; Rolduà-Ros J; Del Cacho-Ortega N; Butjosa A; Muñoz-Samons D; Cuevas-Esteban J; Profep G; Usall J
    J Psychiatr Res; 2023 Apr; 160():171-176. PubMed ID: 36804112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents.
    Meijer J; Simons CJ; Quee PJ; Verweij K;
    Acta Psychiatr Scand; 2012 Jan; 125(1):66-76. PubMed ID: 22013907
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis.
    Lo Cascio N; Saba R; Hauser M; Vernal DL; Al-Jadiri A; Borenstein Y; Sheridan EM; Kishimoto T; Armando M; Vicari S; Fiori Nastro P; Girardi P; Gebhardt E; Kane JM; Auther A; Carrión RE; Cornblatt BA; Schimmelmann BG; Schultze-Lutter F; Correll CU
    Eur Child Adolesc Psychiatry; 2016 Oct; 25(10):1091-102. PubMed ID: 26921232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline.
    Carrión RE; Walder DJ; Auther AM; McLaughlin D; Zyla HO; Adelsheim S; Calkins R; Carter CS; McFarland B; Melton R; Niendam T; Ragland JD; Sale TG; Taylor SF; McFarlane WR; Cornblatt BA
    J Psychiatr Res; 2018 Jan; 96():231-238. PubMed ID: 29121595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between saliva alpha-amylase, heart rate variability, saliva cortisol and cognitive performance in individuals at ultra high-risk for psychosis.
    Almstrup FB; Nordentoft M; Jensen MA; Kristiansen J; Kristensen TD; Wenneberg C; Garde AH; Glenthøj LB; Nordholm D
    Schizophr Res; 2023 May; 255():165-172. PubMed ID: 37001391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis.
    Lin A; Wood SJ; Nelson B; Brewer WJ; Spiliotacopoulos D; Bruxner A; Broussard C; Pantelis C; Yung AR
    Schizophr Res; 2011 Oct; 132(1):1-7. PubMed ID: 21763109
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users.
    Chen CK; Lin SK; Chen YC; Huang MC; Chen TT; Ree SC; Wang LJ
    Drug Alcohol Depend; 2015 Mar; 148():158-64. PubMed ID: 25601645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms.
    Krakauer K; Ebdrup BH; Glenthøj BY; Raghava JM; Nordholm D; Randers L; Rostrup E; Nordentoft M
    Psychol Med; 2017 Nov; 47(15):2689-2707. PubMed ID: 28464976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic liability in individuals at ultra-high risk of psychosis: A comparison study of 9 psychiatric traits.
    Lim K; Lam M; Huang H; Liu J; Lee J
    PLoS One; 2020; 15(12):e0243104. PubMed ID: 33264322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.